Literature DB >> 9384642

A Bayesian approach to Weibull survival models--application to a cancer clinical trial.

K Abrams1, D Ashby, D Errington.   

Abstract

In this paper we outline a class of fully parametric proportional hazards models, in which the baseline hazard is assumed to be a power transform of the time scale, corresponding to assuming that survival times follow a Weibull distribution. Such a class of models allows for the possibility of time varying hazard rates, but assumes a constant hazard ratio. We outline how Bayesian inference proceeds for such a class of models using asymptotic approximations which require only the ability to maximize the joint log posterior density. We apply these models to a clinical trial to assess the efficacy of neutron therapy compared to conventional treatment for patients with tumours of the pelvic region. In this trial there was prior information about the log hazard ratio both in terms of elicited clinical beliefs and the results of previous studies. Finally, we consider a number of extensions to this class of models, in particular the use of alternative baseline functions, and the extension to multi-state data.

Entities:  

Mesh:

Year:  1996        PMID: 9384642     DOI: 10.1007/bf00128573

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  12 in total

1.  On some applications of Bayesian methods in cancer clinical trials.

Authors:  J B Greenhouse
Journal:  Stat Med       Date:  1992-01-15       Impact factor: 2.373

2.  Multistate models in survival analysis: a study of nephropathy and mortality in diabetes.

Authors:  P K Andersen
Journal:  Stat Med       Date:  1988-06       Impact factor: 2.373

3.  Applying Bayesian ideas in drug development and clinical trials.

Authors:  D J Spiegelhalter; L S Freedman; M K Parmar
Journal:  Stat Med       Date:  1993-08       Impact factor: 2.373

4.  Reporting Bayesian analyses of clinical trials.

Authors:  M D Hughes
Journal:  Stat Med       Date:  1993-09-30       Impact factor: 2.373

5.  The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee.

Authors:  M K Parmar; D J Spiegelhalter; L S Freedman
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

6.  An application of Bayesian analysis to medical follow-up data.

Authors:  J A Achcar; R Brookmeyer; W G Hunter
Journal:  Stat Med       Date:  1985 Oct-Dec       Impact factor: 2.373

7.  Tutorial in biostatistics Bayesian data monitoring in clinical trials.

Authors:  P M Fayers; D Ashby; M K Parmar
Journal:  Stat Med       Date:  1997-06-30       Impact factor: 2.373

8.  Early stopping rules--clinical perspectives and ethical considerations.

Authors:  M Baum; J Houghton; K Abrams
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

9.  High energy neutron treatment for pelvic cancers: study stopped because of increased mortality.

Authors:  R D Errington; D Ashby; S M Gore; K R Abrams; S Myint; D E Bonnett; S W Blake; T E Saxton
Journal:  BMJ       Date:  1991-05-04

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

1.  Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

Authors:  P J Newcombe; H Raza Ali; F M Blows; E Provenzano; P D Pharoah; C Caldas; S Richardson
Journal:  Stat Methods Med Res       Date:  2016-09-30       Impact factor: 3.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.